Assessment Of EZH2 Expression In CD34+ Bone Marrow Progenitor Cells Of Patients Of Myelodysplastic Syndromes (MDS)

Yue Wei(The University of Texas MD Anderson Cancer Center), Guillermo Garcia‐Manero(The University of Texas MD Anderson Cancer Center), Hong Zheng(The University of Texas MD Anderson Cancer Center), Hui Yang(Hebei Medical University), Rui Chen(Baylor College of Medicine), Xia Wang(Union Hospital), Hui Wang(Tibet Autonomous Region People's Hospital), Yu Jia(The University of Texas MD Anderson Cancer Center)
Blood
November 15, 2013
10.1182/blood.v122.21.2805.2805
Cited by 0

Related Papers

Genetic Alterations Activating Kinase and Cytokine Receptor Signaling in High-Risk Acute Lymphoblastic Leukemia
|Cancer Cell|2012|722
Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies
|Blood|2009|718
Epigenomic Profiling of Young and Aged HSCs Reveals Concerted Changes during Aging that Reinforce Self-Renewal
|Cell stem cell|2014|703
Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia
|Blood|2006|691
Dnmt3a regulates emotional behavior and spine plasticity in the nucleus accumbens
|Nature Neuroscience|2010|616